The contribution of this study is 2-fold: one is to confirm the possibility of predicting the methylation status of MGMT promoter in gliomas by WSI; second, an end-to-end model was established to simplify the cost of MGMT promoter status detection in glioma patients. Here, MGMT is linked to central nervous system cancer.